Total Payments
$911,940
2024 Payments
$3,758
Companies
48
Transactions
1,122
Medicare Patients
3,364
Medicare Billing
$200,299
Payment Breakdown by Category
Research$847,557 (92.9%)
Other$24,680 (2.7%)
Food & Beverage$22,805 (2.5%)
Consulting$10,958 (1.2%)
Travel$5,436 (0.6%)
Education$504.89 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $847,557 | 113 | 92.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,680 | 12 | 2.7% |
| Food and Beverage | $22,805 | 963 | 2.5% |
| Consulting Fee | $10,958 | 8 | 1.2% |
| Travel and Lodging | $5,436 | 14 | 0.6% |
| Education | $504.89 | 12 | 0.1% |
Payments by Type
Research
$847,557
113 transactions
General
$64,383
1,009 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $604,188 | 21 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $81,775 | 75 | $0 (2019) |
| Taro Pharmaceuticals USA, Inc. | $80,944 | 14 | $0 (2018) |
| Ichnos Sciences Inc. | $71,344 | 6 | $0 (2022) |
| Celgene Corporation | $20,572 | 36 | $0 (2019) |
| PFIZER INC. | $19,988 | 50 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $9,579 | 4 | $0 (2017) |
| UCB, Inc. | $4,852 | 170 | $0 (2024) |
| ABBVIE INC. | $3,937 | 193 | $0 (2024) |
| Janssen Biotech, Inc. | $1,987 | 121 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,758 | 157 | ABBVIE INC. ($693.12) |
| 2023 | $49,273 | 185 | Eli Lilly and Company ($45,090) |
| 2022 | $48,754 | 184 | Eli Lilly and Company ($26,012) |
| 2021 | $406,038 | 139 | Eli Lilly and Company ($391,431) |
| 2020 | $179,616 | 59 | Eli Lilly and Company ($135,957) |
| 2019 | $82,875 | 159 | Glenmark Pharmaceuticals Inc. ($74,220) |
| 2018 | $19,287 | 122 | Glenmark Pharmaceuticals Inc. ($7,554) |
| 2017 | $122,340 | 117 | TARO PHARMACEUTICALS USA, INC. ($80,911) |
All Payment Transactions
1,122 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.55 | General |
| Category: Immunology | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $2.28 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.19 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $22.26 | General |
| 12/04/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: DERMATOLOGY | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $65.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $97.15 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $38.92 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Immunology | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Immunology | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $6.26 | General |
| Category: Immunology | ||||||
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Immunology | ||||||
| 10/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: IMMUNOLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: IMMUNOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.55 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Immunology | ||||||
| 10/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.55 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $427,558 | 7 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $128,404 | 6 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $74,220 | 42 |
| GBR830-204 | Ichnos Sciences Inc. | $53,249 | 4 |
| A PHASE 1 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $40,780 | 1 |
| TaroAZAG 1533 | TARO PHARMACEUTICALS USA, INC. | $39,221 | 6 |
| TaroLCNZ 1618 | TARO PHARMACEUTICALS USA, INC. | $21,230 | 4 |
| ISB830-204 | Ichnos Sciences Inc. | $18,095 | 2 |
| TaroNFTC 1722 | TARO PHARMACEUTICALS USA, INC. | $17,460 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $9,450 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $7,554 | 33 |
| TaroAZAF 1703 | TARO PHARMACEUTICALS USA, INC. | $3,000 | 1 |
| A MULTIPLE-DOSE, RANDOMIZED, PLACEBO-CONTROLLED, STUDY OF LY3462817 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $2,770 | 1 |
| A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $2,587 | 2 |
| A PHASE 2 RANDOMIZED DOUBLE-BLIND PARALLEL-GROUP PLACEBO-CONTROLLED 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $1,641 | 1 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $335.37 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,004 | 1,472 | $212,134 | $63,047 |
| 2022 | 14 | 970 | 1,543 | $206,775 | $59,613 |
| 2021 | 14 | 805 | 1,254 | $162,205 | $47,415 |
| 2020 | 15 | 585 | 902 | $118,499 | $30,224 |
Total Patients
3,364
Total Services
5,171
Medicare Billing
$200,299
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 154 | 185 | $32,371 | $11,718 | 36.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 124 | 139 | $41,700 | $9,861 | 23.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 147 | 199 | $19,900 | $8,171 | 41.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 59 | 74 | $12,950 | $5,956 | 46.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 68 | 68 | $17,000 | $5,050 | 29.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 105 | 113 | $22,527 | $4,592 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 49 | $12,250 | $4,084 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $9,624 | $3,451 | 35.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 25 | 25 | $5,000 | $2,309 | 46.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 44 | 44 | $8,800 | $2,292 | 26.0% |
| 17280 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 11 | 15 | $4,500 | $1,465 | 32.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 72 | 275 | $13,638 | $1,393 | 10.2% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 20 | 28 | $4,200 | $1,076 | 25.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 21 | 27 | $2,700 | $1,039 | 38.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 51 | $1,275 | $476.52 | 37.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 43 | 148 | $3,700 | $114.39 | 3.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 126 | 156 | $27,318 | $9,778 | 35.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 158 | 241 | $24,100 | $9,205 | 38.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 107 | 113 | $33,702 | $7,961 | 23.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 91 | 91 | $22,690 | $6,320 | 27.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 62 | 72 | $12,647 | $6,136 | 48.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 114 | 135 | $26,727 | $5,362 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $11,700 | $4,521 | 38.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 39 | $9,751 | $3,678 | 37.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 51 | 51 | $10,200 | $2,544 | 24.9% |
About Dr. Stephen Schleicher, M.D
Dr. Stephen Schleicher, M.D is a MOHS-Micrographic Surgery healthcare provider based in Sugarloaf, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861487449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Schleicher, M.D has received a total of $911,940 in payments from pharmaceutical and medical device companies, with $3,758 received in 2024. These payments were reported across 1,122 transactions from 48 companies. The most common payment nature is "" ($847,557).
As a Medicare-enrolled provider, Schleicher has provided services to 3,364 Medicare beneficiaries, totaling 5,171 services with total Medicare billing of $200,299. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty MOHS-Micrographic Surgery
- Other Specialties Dermatology
- Location Sugarloaf, PA
- Active Since 09/20/2005
- Last Updated 01/17/2022
- Taxonomy Code 207ND0101X
- Entity Type Individual
- NPI Number 1861487449
Products in Payments
- Topicort Spray 0.25% (Drug) $80,911
- GBR830-204 (Drug) $41,287
- Otezla (Drug) $21,027
- EUCRISA (Drug) $19,846
- TREMFYA (Drug) $1,911
- SKYRIZI (Biological) $1,860
- DUPIXENT (Biological) $1,530
- Cimzia (Drug) $1,155
- TALTZ (Drug) $1,103
- Humira (Biological) $884.47
- ILUMYA (Biological) $837.97
- Tremfya (Drug) $781.79
- RINVOQ (Biological) $716.85
- VTAMA (Drug) $697.62
- Enbrel (Biological) $619.42
- Ilumya (Biological) $561.09
- Xolair (Biological) $533.13
- Bimzelx (Biological) $515.58
- DUPIXENT (Drug) $450.29
- COSENTYX (Drug) $372.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.